DK0708103T3 - Fremgangsmåde til fremstilling af et tetrazolderivat i to krystallinske former og ny krystallinsk form af dette derivat - Google Patents

Fremgangsmåde til fremstilling af et tetrazolderivat i to krystallinske former og ny krystallinsk form af dette derivat

Info

Publication number
DK0708103T3
DK0708103T3 DK95402322T DK95402322T DK0708103T3 DK 0708103 T3 DK0708103 T3 DK 0708103T3 DK 95402322 T DK95402322 T DK 95402322T DK 95402322 T DK95402322 T DK 95402322T DK 0708103 T3 DK0708103 T3 DK 0708103T3
Authority
DK
Denmark
Prior art keywords
derivative
water
ray diffraction
diffraction pattern
contg
Prior art date
Application number
DK95402322T
Other languages
Danish (da)
English (en)
Inventor
Antoine Caron
Dominique Chantreux
Colette Residence Le Bouloumie
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0708103T3 publication Critical patent/DK0708103T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
DK95402322T 1994-10-19 1995-10-18 Fremgangsmåde til fremstilling af et tetrazolderivat i to krystallinske former og ny krystallinsk form af dette derivat DK0708103T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412459A FR2725987B1 (fr) 1994-10-19 1994-10-19 Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Publications (1)

Publication Number Publication Date
DK0708103T3 true DK0708103T3 (da) 2001-04-23

Family

ID=9467986

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95402322T DK0708103T3 (da) 1994-10-19 1995-10-18 Fremgangsmåde til fremstilling af et tetrazolderivat i to krystallinske former og ny krystallinsk form af dette derivat

Country Status (26)

Country Link
US (1) US5629331A (cs)
EP (1) EP0708103B1 (cs)
JP (1) JP3366786B2 (cs)
KR (1) KR100251222B1 (cs)
CN (1) CN1061656C (cs)
AT (1) ATE198478T1 (cs)
AU (1) AU698041B2 (cs)
CA (1) CA2160725C (cs)
CY (1) CY2277B1 (cs)
CZ (2) CZ288629B6 (cs)
DE (1) DE69519788T2 (cs)
DK (1) DK0708103T3 (cs)
ES (1) ES2155115T3 (cs)
FI (1) FI114156B (cs)
FR (1) FR2725987B1 (cs)
GR (1) GR3035503T3 (cs)
HU (1) HU226461B1 (cs)
IL (1) IL115688A (cs)
NO (1) NO307516B1 (cs)
NZ (1) NZ280293A (cs)
PL (1) PL184193B1 (cs)
PT (1) PT708103E (cs)
RU (1) RU2144536C1 (cs)
SI (1) SI0708103T1 (cs)
TW (1) TW357147B (cs)
ZA (1) ZA958850B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
PL205715B1 (pl) * 2000-07-19 2010-05-31 Novartis Ag Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli
EP1453826A1 (en) * 2001-12-10 2004-09-08 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-[[2-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4'] non-1-en-4-one
ES2273041T3 (es) * 2002-07-16 2007-05-01 Teva Pharmaceutical Industries Ltd. Nueva sintesis de irbesartan.
EP2189457A1 (en) * 2003-01-16 2010-05-26 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
PT1590343E (pt) * 2003-02-05 2008-09-11 Teva Pharma Síntese de 2-butil-3-(2¿-(1-tritil-1h-tetrazol-5-il)bifenil-4-il)-1,3-diazaspiro-4,4-non-en-4-ona
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
PL379420A1 (pl) * 2003-07-31 2006-09-04 Nicox S.A. Pochodne blokerów receptora angiotensyny II
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005051943A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Processes for the preparation of highly pure irbesartan
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006001026A1 (en) * 2004-06-23 2006-01-05 Hetero Drugs Limited Irbesartan polymorphs
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
ES2454197T3 (es) 2004-11-11 2014-04-09 Lek Pharmaceuticals D.D. Formas polimórficas de Irbesartán
ES2259909B1 (es) * 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
WO2007013101A1 (en) * 2005-07-27 2007-02-01 Jubilant Organosys Limited PROCESS FOR PRODUCING 2-(N-BUTYL)-3-[[2'-(TETRAZOL-5-YL)BIPHENYL- 4-YL]METHYL]-l,3-DIAZASPIRO[4.4] NON-1-EN-4-ONE
PL1806130T3 (pl) 2006-01-09 2010-08-31 Krka D D Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
PL2065035T3 (pl) * 2007-11-28 2011-02-28 Lesvi Laboratorios Sl Preparaty farmaceutyczne zawierające irbesartan
WO2009072137A2 (en) * 2007-12-07 2009-06-11 Hetero Drugs Limited Process for pure irbesartan
KR101009383B1 (ko) * 2008-04-30 2011-01-19 켐젠주식회사 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법
EP2417110B1 (en) * 2009-04-08 2014-05-07 CTX Life Sciences Pvt. Ltd. A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4]non-1-en-4-one (irbesartan)
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
US8080670B2 (en) 2010-05-04 2011-12-20 Divi's Laboratories, Ltd. Process for the preparation of irbesartan
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
CN118556049A (zh) 2021-10-01 2024-08-27 赛诺菲 用于制备具有四唑环的沙坦活性化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
JP2697919B2 (ja) * 1989-09-29 1998-01-19 キヤノン株式会社 信号内挿回路及び該回路を備えた変位測定装置
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
TW201738B (cs) * 1990-03-20 1993-03-11 Sanofi Co
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
EP0708103A1 (fr) 1996-04-24
FR2725987B1 (fr) 1997-01-10
EP0708103B1 (fr) 2001-01-03
FI954992L (fi) 1996-04-20
ES2155115T3 (es) 2001-05-01
AU698041B2 (en) 1998-10-22
KR100251222B1 (ko) 2000-05-01
DE69519788D1 (de) 2001-02-08
CA2160725A1 (en) 1996-04-20
PT708103E (pt) 2001-06-29
ATE198478T1 (de) 2001-01-15
HU226461B1 (en) 2008-12-29
NO307516B1 (no) 2000-04-17
ZA958850B (en) 1996-05-27
NO954154L (no) 1996-04-22
HU9503016D0 (en) 1995-12-28
FI954992A0 (fi) 1995-10-19
IL115688A0 (en) 1996-01-19
NZ280293A (en) 1997-10-24
NO954154D0 (no) 1995-10-18
US5629331A (en) 1997-05-13
CN1061656C (zh) 2001-02-07
HK1005135A1 (en) 1998-12-24
FI114156B (fi) 2004-08-31
HUT73179A (en) 1996-06-28
PL184193B1 (pl) 2002-09-30
RU2144536C1 (ru) 2000-01-20
CN1128261A (zh) 1996-08-07
AU3433595A (en) 1996-05-02
IL115688A (en) 1999-09-22
CZ271095A3 (en) 1996-05-15
CZ288624B6 (cs) 2001-08-15
JP3366786B2 (ja) 2003-01-14
CA2160725C (en) 2001-12-18
SI0708103T1 (en) 2001-04-30
JPH08208642A (ja) 1996-08-13
KR960014122A (ko) 1996-05-22
CZ288629B6 (cs) 2001-08-15
PL311012A1 (en) 1996-04-29
DE69519788T2 (de) 2001-08-30
TW357147B (en) 1999-05-01
FR2725987A1 (fr) 1996-04-26
GR3035503T3 (en) 2001-06-29
CY2277B1 (en) 2003-07-04

Similar Documents

Publication Publication Date Title
DK0708103T3 (da) Fremgangsmåde til fremstilling af et tetrazolderivat i to krystallinske former og ny krystallinsk form af dette derivat
RU95118109A (ru) Способ получения производного тетразола, способ получения формы b производного тетразола, форма b производного тетразола и фармацевтическая композиция на основе производного тетразола формы b
IT1311837B1 (it) Dispositivo di attracco per veicoli autonomi sottomarini semoventi
ATE240323T1 (de) Heterozyklische verbindungen, verfahren zu deren herstellung und deren anwendung als angiotensin- ii-antagonist
PE46497A1 (es) ANTAGONISTAS a1-ADRENOCEPTORES, SUS EMPLEOS COMO AGENTES TERAPEUTICOS Y LOS METODOS DE SU PREPARACION
NO973813L (no) Fremgangsmåte ved gjenvinning av xylose fra opplösninger
FR2804935B1 (fr) Procede et installation de recuperation d'effluents en mer
DK0643704T3 (da) Tetrazolylphenylboronsyremellemprodukter til syntese af All-receptor antagonister
DK0889874T3 (da) 7-Amino-2-heptenoater og anvendelse deraf ved fremstillingen af methylphenidat
RU2004128935A (ru) Способ получения производных фенилаланина и их полупродуктов
ATE243685T1 (de) Verfahren zur herstellung von 2-chlor-5- chlormethylthiazol
DK0767140T3 (da) Fremgangsmåde til genudvinding af saltbestanddelene fra hærderisaltbade
KR100809159B1 (ko) 로사탄의 개선된 제조방법
ZA200105406B (en) Method of producing cyclene.
NO983285L (no) Pyrido-1,2,4-tiadiazin- og pyrido-1,4-tiazinderivater, deres fremstilling og anvendelse
KR840003250A (ko) 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법
US6156890A (en) Process for the production of cyclene
DK0442378T3 (da) Selektive fremgangsmåder til fosinoprilpolymorfe
JP2001062467A5 (cs)
NO881163L (no) Fremgangsmaate for oppnaaelse av opploeste salter og syrer fra andre tilgjengelige slike, ved hjelp av ioneutvekslingsharpikser.
Li et al. Synthesis of l-Arylaminoacetyl-4-arylacetyl Thiosemicarbazides
RU99105624A (ru) Антигеопатогенное покрывало "нейтрализатор"
ITPD940123V0 (it) Attrezzatura per la veicolazione autonoma sull'acqua, mediante propul-sione muscolare, di uno o piu' utenti.